Document Detail


High density lipoprotein cholesterol and apolipoprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitor.
MedLine Citation:
PMID:  19138801     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Although a low level of high density lipoprotein-cholesterol (HDL-C) is an important risk factor for coronary heart disease, few available agents are capable of significantly increasing HDL-C. This multicenter study demonstrated that administration of pitavastatin, a new HMG-CoA reductase inhibitor, significantly and persistently increased HDL-C (from 36.0+/-5.9 to 40.5+/-9.1 mg/dL: p<0.001) and apolipoprotein A-I levels (from 108.4+/-18.0 to 118.7+/-19.3 mg/dL: p<0.01) in 43 hypercholesterolemic patients with low HDL-C over the course of 12 months of treatment. This suggests that pitavastatin may contribute to reduction in coronary heart disease.
Authors:
Tatsuya Fukutomi; Yutaka Takeda; Shogo Suzuki; Tatsuya Ito; Takashi Joh; Makoto Itoh
Publication Detail:
Type:  Clinical Trial; Letter; Multicenter Study     Date:  2009-01-12
Journal Detail:
Title:  International journal of cardiology     Volume:  141     ISSN:  1874-1754     ISO Abbreviation:  Int. J. Cardiol.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-05-31     Completed Date:  2010-09-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8200291     Medline TA:  Int J Cardiol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  320-2     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2008 Elsevier Ireland Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Apolipoprotein A-I / blood*
Cholesterol, HDL / blood*
Coronary Disease / blood,  drug therapy*
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hypercholesterolemia / blood,  drug therapy*
Male
Middle Aged
Quinolines / therapeutic use*
Chemical
Reg. No./Substance:
0/Apolipoprotein A-I; 0/Cholesterol, HDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Quinolines; 147526-32-7/NK 104

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Anti-brain antibodies in adult patients with obsessive-compulsive disorder.
Next Document:  Association of matrix metalloproteinase-3 with cardiogenic activity during Noggin-induced differenti...